awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
J.YGYNO.2015.03.042
J.YGYNO.2015.03.042
http://dx.doi.org/10.1016/J.YGYNO.2015.03.042
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An
P356
Q27302763-A6466622-5EC2-4343-AAA5-BEC4DDDAB728
P356
J.YGYNO.2015.03.042
http://dx.doi.org/10.1016/J.YGYNO.2015.03.042